Wall Street analyst estimates for Zai Lab Limited (ZLAB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.56 | ||
| 2026-08-06 | $-0.46 | $-0.68 | +32.3% |
| 2026-05-07 | $-0.46 | $-0.53 | +12.6% |
| 2026-02-26 | $-0.46 | $-0.44 | -4.5% |
| 2025-11-06 | $-0.33 | $-0.28 | -17.9% |
| 2025-08-07 | $-0.37 | $-0.37 | +0.0% |
| 2025-05-08 | $-0.45 | $-0.50 | +10.0% |
| 2025-02-27 | $-0.80 | $-0.61 | -31.1% |
Valuation Ratios
| Price / Book | 2.76 |
| EV / EBITDA | -9.33 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $129452 | $13.0M | $49.0M | $144.3M | $215.0M | $266.7M | $399.0M | $460.2M |
| Cost of Revenue | 0 | 0 | $43590 | $3.7M | $239.4M | $52.2M | $74.0M | $95.8M | $147.9M | $191.1M |
| Gross Profit | 0 | 0 | $85862 | $9.2M | -$190.5M | $92.1M | $141.0M | $170.9M | $251.1M | $269.1M |
| Research & Development | $32.1M | $39.3M | $120.3M | $142.2M | $222.7M | $573.3M | $286.4M | $265.9M | $234.5M | $220.9M |
| Selling, General & Admin | $6.4M | $12.0M | $21.6M | $70.2M | $111.3M | $218.8M | $259.0M | $281.6M | $298.7M | $277.6M |
| Operating Expenses | $38.5M | $51.4M | $141.9M | $212.4M | $111.3M | $792.1M | $545.4M | $537.5M | $533.2M | $492.6M |
| Operating Income | -$38.5M | -$51.4M | -$141.8M | -$203.2M | -$301.8M | -$700.1M | -$404.4M | -$366.6M | -$282.1M | -$223.6M |
| EBITDA | -$38.3M | -$50.8M | -$138.4M | -$190.3M | -$297.2M | -$689.5M | -$434.8M | -$365.1M | -$234.6M | -$158.2M |
| Interest Expense | 0 | 0 | $39672 | $293000 | $181000 | 0 | 0 | 0 | $2.3M | $5.2M |
| Pre-tax Income | -$37.5M | -$50.1M | -$138.5M | -$206.0M | -$268.9M | -$703.4M | -$443.3M | -$334.6M | -$257.1M | -$178.5M |
| Income Tax | 0 | $477699 | $3.3M | -$11.0M | 0 | $1.1M | 0 | 0 | 0 | -$2.9M |
| Net Income | -$37.5M | -$50.4M | -$139.1M | -$195.1M | -$268.9M | -$704.5M | -$443.3M | -$334.6M | -$257.1M | -$175.5M |
| EPS | $-39.70 | $-23.20 | $-26.40 | $-30.30 | $-34.60 | $-75.80 | $-46.30 | $-34.60 | $-2.60 | $-1.60 |
| EPS (Diluted) | $-39.70 | $-23.20 | $-26.40 | $-30.30 | $-34.60 | $-75.80 | $-46.30 | $-34.60 | $-2.60 | $-1.60 |
| Shares Outstanding (Diluted) | $943902 | $2.2M | $5.3M | $6.4M | $7.8M | $9.3M | $9.6M | $9.7M | $98.9M | $109.5M |
Price
| Price | $24.67 |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | CN |
Related companies: AAPG · APGE · CDTX · CNTA · IDYA · IRON · LEGN
Explore sector: Healthcare · Biotechnology
More sections of ZLAB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks